Pharmacodynamic Evaluation of the Target Efficacy of SB939, an Oral HDAC Inhibitor with Selectivity for Tumor Tissue

  • K. Ethirajulu, J. Zhu, J. M. Wood, V. Novotny-Diermayr, N. Sausgruber, Y. K. Loh, M. K. Pasha, R. Jayaraman, H. Hentze, W.-P. Yong, B.-C. Goh, H.-C. Toh
  • Molecular Cancer Therapeutics, May 2011, American Association for Cancer Research (AACR)
  • DOI: 10.1158/1535-7163.mct-11-0044

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication

The following have contributed to this page: Dr veronica diermayr